Company

Jiangsu Xinlikang Medical Technology Co., Ltd. was founded in November 2014 with a registered capital of 115 million yuan and a total area of 4147.5 square meters. It is a high-tech company based on the field of new medical bio-renewable materials, integrating R&D, production and commercialization. The company is led by Dr. Dong Ruiping, an expert of the 12th batch of "Thousand People Program" of the state. It has 11 global patents, invested more than 100 million RMB in the initial stage, built three technical platforms, imported full sets of production equipment from the European Union (Germany), and devoted itself to establishing a modern plant conforming to the GMP certification of China and the European Union.

In the next few years, Jiangsu Xinlikang will continue to make full use of the preferential policies and capital of the state, constantly optimize the enterprise structure, further product development and enrich the product variety to maintain the sustained competitiveness of products in the global market, and strive to merge with the world's top medical equipment enterprises. Shoulder development, and provide the best health service products for Chinese and even global patients.

Xin Li Kang began to create the world's first inorganic biodegradable new medical biological regeneration material -- SGF silica gel fiber. Its advanced originality can be used to promote wound healing and scar formation. The product has been certified by European Union CE (IIB), suitable for the treatment of chronic wounds, bedsores, lower limb venous ulcers, diabetic foot ulcers, second degree burns and other healing purposes. In addition, it can also be used for bone and joint repair (as a platform / carrier combined with drugs) in the prevention of wound infection, hemostasis / analgesic acute wounds, etc., to meet different clinical use, taking into account short, medium and long-term needs. The product is expected to complete clinical trials in 2019 and will be available in 2020.

At the same time, invest in the US OptMmed company to obtain the Greater China interests of its adhesive product BondEase. The postoperative adhesive products are in a leading position in the world, while complementing SGF carrier effectively, creating a wound treatment product chain, enhance the company's comprehensive competitiveness.

In addition, the company builds a second class of active electronic medical equipment products - - air wave pressure therapy device using intermittent air pressure circulation massage mode, so that blood vessels can be perfused, improve and promote lower limb blood circulation, speed up blood flow, so that the leg blood circulation is normal, metabolites can be timely taken away by the blood. It is helpful to prevent thrombosis, limb edema, and can directly or indirectly treat many diseases related to blood lymph circulation.